Skip to main content
. 2022 Oct 7;101(40):e30590. doi: 10.1097/MD.0000000000030590

Table 2.

Efficacy and safety of vedolizumab versus placebo for IBD.

Category Subgroup RR (95% CI) P I 2
Induction therapy
Clinical/CDAI-100 response UC 1.62 (1.33–1.97) <.05 43%
CD 1.49 (1.23–1.80) <.05 2%
Mucosal healing UC 1.53 (1.21–1.95) <.05 28%
CD NA
Maintenance therapy
Durable clinical remission UC 2.12 (1.06–4.25) <.05 0%
CD 1.31 (0.86–2.01) .21 0%
Clinical/CDAI-100 response UC 2.15 (1.56–2.96) <.05 0%
CD 1.34 (1.13–1.59) <.05 59%
Glucocorticoid-free remission UC 2.44 (1.61–3.71) <.05 0%
CD 2.09 (1.48–2.94) <.05 0%
Safety
Adverse events UC 1.03 (0.97–1.10) .34 47%
CD 1.00 (0.92–1.08) .90 13%
Disease exacerbation UC 0.90 (0.59–1.37) .63 68%
CD 0.64 (0.40–1.03) .07 70%
Serious adverse events UC 1.05 (0.78–1.42) .08 0%
CD 1.22 (0.97–1.52) .08 57%
Serious infection UC 0.68 (0.30–1.51) .34 0%
CD 1.12 (0.27–4.71) .87 69%

CD = Crohn disease, CDAI = CD Activity Index, CI = confidence interval, IBD = inflammatory bowel disease, NA = not applicable, RR = relative risk, UC = ulcerative colitis.